Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with preserved ejection fraction, regardless of diabetes status.
Does empagliflozin reduce the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction?
Empagliflozin reduces the composite risk of cardiovascular death or heart failure hospitalization in patients with HFpEF, independent of diabetes status.
Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes. (Funded by Boehringer Ingelheim and Eli Lilly; EMPEROR-Preserved ClinicalTrials.gov number, NCT03057951).
Anker et al. (2021) studied this question. Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with preserved ejection fraction, regardless of diabetes status.